12/29/2011 | PP | Marshall Edwards to sell $2 million stock through private placement
|
9/29/2011 | PP | Marshall Edwards details $2 million private placement of common stock
|
9/28/2011 | PP | Marshall Edwards to pocket $2 million via private placement of stock
|
5/16/2011 | PP | Marshall Edwards removes C warrants from $1.11 million placement
|
5/2/2011 | PP | Marshall Edwards negotiates $1.11 million private placement of stock
|
4/1/2011 | CVPF | Marshall Edwards files $50 million shelf covering stock, preferreds
|
3/18/2011 | PP | Marshall Edwards plans $1.74 million stock, preferreds direct offering
|
7/30/2008 | PP | New Issue: Marshall Edwards plans $10 million private placement of shares
|
3/19/2008 | CVHY | Marshall Edwards files $75 million shelf registration
|
8/6/2007 | PP | New Issue: Marshall Edwards to complete $16.4 million placement of stock
|
9/18/2006 | BT | Novogen: Phenoxodiol targets prostate cancer protein
|
7/13/2006 | PP | Market Commentary: G-III Apparel secures $15.16 million from stock offering; Canadian economy sets PIPE pricing back
|
7/12/2006 | BT | Market Commentary: Genzyme, Genentech 2Q results counteract; Curis retraces losses; Antigenics, CV, Cell Genesys up
|
7/12/2006 | PP | Market Commentary: Marshall Edwards sells $18.35 million in stock; Edgewater Foods seals $5.4 million PIPE
|
7/12/2006 | BTPP | New Issue: Marshall Edwards gets equity line, sells $4 million of stock
|
7/12/2006 | BTPP | New Issue: Marshall Edwards raises $14.35 million from placement of shares
|
6/7/2006 | BT | Novogen renegotiates timing of Marshall Edwards' license payment for phenoxodiol
|
5/16/2006 | BT | FDA approves Marshall Edwards' Ovature study design for phenoxodiol in ovarian cancer
|
5/15/2006 | BT | Marshall Edwards licenses two anticancer compounds from Novogen
|
3/29/2006 | BT | Novogen, Marshall Edwards to bring ovarian cancer drug to market
|
1/11/2006 | BT | Market Commentary: PDL, OSI Pharma, Biogen dive; Altus IPO launches, Vertex eases; Novogen shelves Glycotex IPO
|
11/28/2005 | BT | Marshall Edwards, Sanofi-Aventis plan trial of phenoxodiol with docetaxel for ovarian cancer
|